Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Krugmann



Author of

  • +

    P2.03a - Poster Session with Presenters Present (ID 464)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.03a-060 - Favorable Survival of TTF-1 Expression in Pemetrexed Based Treated NSCLC Patients (ID 5368)

      14:30 - 14:30  |  Author(s): J. Krugmann

      • Abstract

      Background:
      The translational research analysis of the Pointbreak study could demonstrate superior overall survival (OS) for TTF-1 expressing NSCLC in comparison to TTF1-1 negatives treated with Pemetrexed based chemotherapy. The aim of this study was to prove retrospectively whether this finding can be reproduced in patients from the daily clinical practice in three different german hospitals.

      Methods:
      323 patients (pts), 182m, 141f, median age 64 years (34-84) with non-sqamous NSCLC stage UICC IIIB/IV undergoing pemetrexed based palliative chemotherapy were analyzed for TTF- 1 expression by immunohistochemistry and outcome.

      Results:
      246 pts (76%) were TTF-1 positive, well balanced for for age and gender. Median number of administered chemotherapy cycles was 4 in both groups; 19 pts (5.9%) received maintenance therapy. Response was superior in TTF-1 expressing (vs non-expressing) patients (CR 2% vs. 6%, PR 58% vs. 39%, NC 21% vs. 16%, PD 19% vs. 39%, X[2]=14.4, p<0.002) as well as OS (MST 14.5m vs. 8.3m, HR=0.44, CI 0.33-0.58, p<0.0001) and progression free survival (PFS: MST 7.7m vs. 4.8m, HR 0.51, CI 0.35-0.74, p<0.001). 1-y and 2-y OS were 59% and 23% for TTF-1 expressing pts compared to 34% and 0%, respectively In multivariate analysis TTF-1 expression (HR= 0.43, CI 0.30 - 0.63, p<0.0001) and 4 vs. 6 cycles of chemotherapy (HR=0.81, CI 0.70 - 0.95, p=0.009) were the only independent factors for OS. For PFS TTF-1 expression was the only independent predictive factor (HR=0.49, CI 0.31-0.77, p=0.002).

      Conclusion:
      These results confirm the relevance of TTF-1 expression on outcome in pemetrexed based chemotherapy with TTF-1 being of significant independent prognostic relevance. Further analyses with TTF-1 in non pemetrexed treated patients are ongoing to evaluate its predictive value.